Leonard Amaral

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8678048/publications.pdf

Version: 2024-02-01

193 papers	7,985 citations	38742 50 h-index	64796 79 g-index
196 all docs	196 docs citations	196 times ranked	6650 citing authors

#	Article	IF	Citations
1	The Role of Efflux Pumps and Environmental pH in Bacterial Multidrug Resistance. In Vivo, 2020, 34, 65-71.	1.3	10
2	New Roads Leading to Old Destinations: Efflux Pumps as Targets to Reverse Multidrug Resistance in Bacteria. Molecules, 2017, 22, 468.	3.8	142
3	Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action. Antibiotics, 2017, 6, 3.	3.7	57
4	Possible Biological and Clinical Applications of Phenothiazines. Anticancer Research, 2017, 37, 5983-5993.	1.1	73
5	Identification of selenocompounds with promising properties to reverse cancer multidrug resistance. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2821-2824.	2.2	53
6	Thioridazine Alters the Cell-Envelope Permeability of Mycobacterium tuberculosis. Journal of Proteome Research, 2016, 15, 1776-1786.	3.7	25
7	Laser beam resonant interaction of new hydantoin derivatives droplets for possible biomedical applications. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2016, 505, 37-46.	4.7	3
8	Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter. Methods in Molecular Biology, 2016, 1395, 87-103.	0.9	9
9	Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. PLoS ONE, 2016, 11, e0149326.	2.5	68
10	Identification of Important Compounds Isolated from Natural Sources that Have Activity Against Multidrug-resistant Cancer Cell Lines: Effects on Proliferation, Apoptotic Mechanism and the Efflux Pump Responsible for Multi-resistance Phenotype. Anticancer Research, 2016, 36, 5665-5672.	1.1	14
11	The Anticancer Activity of the Old Neuroleptic Phenothiazine-type Drug Thioridazine. Anticancer Research, 2016, 36, 5701-5706.	1.1	40
12	Ecdysteroids Sensitize MDR and Non-MDR Cancer Cell Lines to Doxorubicin, Paclitaxel, and Vincristine but Tend to Protect Them from Cisplatin. BioMed Research International, 2015, 2015, 1-8.	1.9	27
13	Imidazolidine-4-one derivatives in the search for novel chemosensitizers of Staphylococcus aureus MRSA: Synthesis, biological evaluation and molecular modeling studies. European Journal of Medicinal Chemistry, 2015, 101, 313-325.	5.5	22
14	Reversal of ABCB1-related Multidrug Resistance of Colonic Adenocarcinoma Cells by Phenothiazines. Anticancer Research, 2015, 35, 3245-51.	1.1	22
15	Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them. Frontiers in Pharmacology, 2014, 4, 168.	3.5	108
16	Characterization of mixtures of compounds produced in chlorpromazine aqueous solutions by ultraviolet laser irradiation: their applications in antimicrobial assays. Journal of Biomedical Optics, 2014, 20, 1.	2.6	21
17	Advances in Personalised Treatment of Multi-drug Resistant Tuberculosis. Biochemistry & Pharmacology: Open Access, 2014, 03, .	0.2	0
18	Rapid, laser-induced conversion of 20-hydroxyecdysone â€“ A follow-up study on the products obtained. Steroids, 2014, 89, 56-62.	1.8	13

#	Article	IF	Citations
19	The Mechanism by which the Phenothiazine Thioridazine Contributes to Cure Problematic Drug-Resistant Forms of Pulmonary Tuberculosis: Recent Patents for â€œNew Useâ€• Recent Patents on Anti-infective Drug Discovery, 2014, 8, 206-212.	0.8	2
20	Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis. In Vivo, 2014, 28, 267-71.	1.3	6
21	Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells. Anticancer Research, 2014, 34, 1737-41.	1.1	9
22	Role of Phenothiazines and Structurally Similar Compounds of Plant Origin in the Fight against Infections by Drug Resistant Bacteria. Antibiotics, 2013, 2, 58-72.	3.7	41
23	Synthesis and Structure-Activity Relationships of Novel Ecdysteroid Dioxolanes as MDR Modulators in Cancer. Molecules, 2013, 18, 15255-15275.	3.8	24
24	Description of plasmid pSM52, harbouring the gene for the Smr efflux pump, and its involvement in resistance to biocides in a meticillin-resistant Staphylococcus aureus strain. International Journal of Antimicrobial Agents, 2013, 41, 490-492.	2.5	22
25	Activity of the efflux pump inhibitor SILA 421 against drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2013, 41, 488-489.	2.5	13
26	Resistance to Antimicrobials Mediated by Efflux Pumps in Staphylococcus aureus. Antibiotics, 2013, 2, 83-99.	3.7	33
27	Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiology Journal, 2013, 7, 59-71.	0.7	314
28	Photobactericidesâ€”A Local Option against Multi-Drug Resistant Bacteria. Antibiotics, 2013, 2, 182-190.	3.7	5
29	A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps. Open Microbiology Journal, 2013, 7, 72-82.	0.7	97
30	Exposure of Chlorpromazine to 266 nm Laser Beam Generates New Species with Antibacterial Properties: Contributions to Development of a New Process for Drug Discovery. PLoS ONE, 2013, 8, e55767.	2.5	25
31	Mechanisms of Resistance in Bacteria: An Evolutionary Approach. Open Microbiology Journal, 2013, 7, 53-58.	0.7	23
32	Preface - Regulation and Control of Efflux Pumps that Mediate Multi-drug Resis-tance of Pathogenic Bacteria. Open Microbiology Journal, 2013, 7, 21-21.	0.7	0
33	Effects of two disiloxanes ALIS-409 and ALIS-421 on chemoprevention in model experiments. Anticancer Research, 2013, 33, 2021-7.	1.1	2
34	The in vitro activity of products formed from exposure of chlorpromazine to a 266 nm laser beam against species of mycobacteria of human interest. In Vivo, 2013, 27, 605-10.	1.3	5
35	Effect of thioridazine stereoisomers on the drug accumulation of mouse lymphoma and human prostate cancer cell lines in vitro. In Vivo, 2013, 27, 815-20.	1.3	9
36	Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals, 2012, 5, 1021-1031.	3.8	14

#	Article	IF	Citations
37	The added effect of thioridazine in the treatment of drug-resistant tuberculosis [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1706-1708.	1.2	20
38	Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2012, 10, 869-873.	4.4	9
39	Selective hydroboration of dieneamines. Formation of hydroxyalkylphenothiazines as MDR modulators. Bioorganic and Medicinal Chemistry, 2012, 20, 4258-4270.	3.0	3
40	Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis. PLoS ONE, 2012, 7, e34538.	2.5	177
41	Genetic response of Salmonella enterica serotype Enteritidis to thioridazine rendering the organism resistant to the agent. International Journal of Antimicrobial Agents, 2012, 39, 16-21.	2.5	21
42	Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. International Journal of Antimicrobial Agents, 2012, 39, 376-380.	2.5	67
43	Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs. Expert Review of Anti-Infective Therapy, 2012, 10, 983-998.	4.4	79
44	A Cheap and Effective Anti-Mdr/Xdr/Tdr Tb Drug is Already Available. Biochemistry & Pharmacology: Open Access, 2012, 01, .	0.2	3
45	Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infection, Genetics and Evolution, 2012, 12, 695-700.	2.3	106
46	Screening for efflux pump systems of bacteria by the new acridine orange agar method. In Vivo, 2012, 26, 203-6.	1.3	7
47	The activity of 16 new hydantoin compounds on the intrinsic and overexpressed efflux pump system of Staphylococcus aureus. In Vivo, 2012, 26, 223-9.	1.3	9
48	Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine. In Vivo, 2012, 26, 231-6.	1.3	15
49	Inhibition of quorum sensing and efflux pump system by trifluoromethyl ketone proton pump inhibitors. In Vivo, 2012, 26, 277-85.	1.3	27
50	Activity of fourteen new hydantoin compounds on the human ABCB1 efflux pump. In Vivo, 2012, 26, 293-7.	1.3	3
51	5-arylidene(thio)hydantoin derivatives as modulators of cancer efflux pump. Acta Poloniae Pharmaceutica, 2012, 69, 149-56.	0.1	7
52	Inhibitors of bacterial efflux pumps that also inhibit efflux pumps of cancer cells. Anticancer Research, 2012, 32, 2947-57.	1.1	16
53	Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis. Acta Medica Portuguesa, 2012, 25, 118-21.	0.4	7
54	Inhibition of efflux pumps in meticillin-resistant Staphylococcus aureus and Enterococcus faecalis resistant strains by triterpenoids from Momordica balsamina. International Journal of Antimicrobial Agents, 2011, 37, 70-74.	2.5	61

#	Article	IF	Citations
55	Role of calcium in the efflux system of Escherichia coli. International Journal of Antimicrobial Agents, 2011, 37, 410-414.	2.5	41
56	Antibacterial properties of compounds isolated from Carpobrotus edulis. International Journal of Antimicrobial Agents, 2011, 37, 438-444.	2.5	46
57	Ethidium bromide efflux by Salmonella: modulation by metabolic energy, pH, ions and phenothiazines. International Journal of Antimicrobial Agents, 2011, 38, 140-145.	2.5	32
58	Foreword. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 76-76.	0.8	1
59	Optical investigation of medicine solutions in micro-droplets form at interaction with laser radiation. Proceedings of SPIE, 2011, , .	0.8	0
60	Mechanisms of Antibiotic Resistance in Salmonella: Efflux Pumps, Genetics, Quorum Sensing and Biofilm Formation. Letters in Drug Design and Discovery, 2011, 8, 114-123.	0.7	14
61	Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiology, 2011, 11, 241.	3.3	93
62	Ethidium bromide transport across Mycobacterium smegmatiscell-wall: correlation with antibiotic resistance. BMC Microbiology, 2011, 11, 35.	3.3	101
63	An Original Deal for New Molecule: Reversal of Efflux Pump Activity, A Rational Strategy to Combat Gram-Negative Resistant Bacteria. Current Medicinal Chemistry, 2011, 18, 2969-2980.	2.4	47
64	Efflux Pumps of Gramâ€Negative Bacteria: Genetic Responses to Stress and the Modulation of their Activity by pH, Inhibitors, and Phenothiazines. Advances in Enzymology and Related Areas of Molecular Biology, 2011, 77, 61-108.	1.3	41
65	Quorum Sensing Inhibition by Phenothiazines and Related Compounds. Letters in Drug Design and Discovery, 2011, 8, 133-137.	0.7	9
66	Direct Modification of Bioactive Phenothiazines by Exposure to Laser Radiation. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 147-157.	0.8	19
67	Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of “New Uses”. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 84-87.	0.8	6
68	Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 118-127.	0.8	45
69	New Patentable Use of an Old Neuroleptic Compound Thioridazine to Combat Tuberculosis: A Gene Regulation Perspective. Recent Patents on Anti-infective Drug Discovery, 2011, 6, 128-138.	0.8	27
70	Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient. Letters in Drug Design and Discovery, 2011, 8, 130-132.	0.7	1
71	BM0701: Antibiotic Transport and Efflux: New Strategies to Combat Bacterial Resistance (ATENS). Letters in Drug Design and Discovery, 2011, 8, 101-101.	0.7	0
72	Identification of efflux pump-mediated multidrug-resistant bacteria by the ethidium bromide-agar cartwheel method. In Vivo, 2011, 25, 171-8.	1.3	41

#	Article	IF	Citations
73	Competition between substrates of the efflux pump system of Salmonella enteritidis. In Vivo, 2011, 25, 597-602.	1.3	5
74	Evaluation of forty new phenothiazine derivatives for activity against intrinsic efflux pump systems of reference Escherichia coli, Salmonella Enteritidis, Enterococcus faecalis and Staphylococcus aureus strains. In Vivo, 2011, 25, 719-24.	1.3	17
75	Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis NCTC 13349. In Vivo, 2011, 25, 769-72.	1.3	23
76	Modulation of multidrug efflux pump activity by new hydantoin derivatives on colon adenocarcinoma cells without inducing apoptosis. Anticancer Research, 2011, 31, 3285-8.	1.1	15
77	Thioridazine induces apoptosis of multidrug-resistant mouse lymphoma cells transfected with the human ABCB1 and inhibits the expression of P-glycoprotein. Anticancer Research, 2011, 31, 4201-5.	1.1	24
78	Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”. Recent Patents on Anti-infective Drug Discovery, 2010, 5, 109-114.	0.8	11
79	Inhibition of quorumâ€sensing signals by essential oils. Phytotherapy Research, 2010, 24, 782-786.	5.8	118
80	Identification of nontuberculous mycobacteria in clinical samples using molecular methods: a 3-year study. Clinical Microbiology and Infection, 2010, 16, 1161-1164.	6.0	28
81	Characterization of antimicrobial resistance in Salmonella enterica food and animal isolates from Colombia: identification of a qnrB19-mediated quinolone resistance marker in two novel serovars. FEMS Microbiology Letters, 2010, 313, 10-19.	1.8	55
82	Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. Expert Review of Anti-Infective Therapy, 2010, 8, 465-480.	4.4	13
83	Thioridazine protects the mouse from a virulent infection by Salmonella enterica serovar Typhimurium 74. International Journal of Antimicrobial Agents, 2010, 35, 174-176.	2.5	23
84	Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!. International Journal of Antimicrobial Agents, 2010, 35, 524-526.	2.5	76
85	Quinazoline derivatives are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. International Journal of Antimicrobial Agents, 2010, 36, 164-168.	2.5	54
86	Physiological characterisation of the efflux pump system of antibiotic-susceptible and multidrug-resistant Enterobacter aerogenes. International Journal of Antimicrobial Agents, 2010, 36, 313-318.	2.5	14
87	Identification of the plasmid-encoded qacA efflux pump gene in meticillin-resistant Staphylococcus aureus (MRSA) strain HPV107, a representative of the MRSA Iberian clone. International Journal of Antimicrobial Agents, 2010, 36, 557-561.	2.5	23
88	The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis. PLoS ONE, 2010, 5, e12640.	2.5	81
89	Evaluation of Efflux Activity of Bacteria by a Semi-automated Fluorometric System. Methods in Molecular Biology, 2010, 642, 159-172.	0.9	66
90	Identification of Efflux-Mediated Multi-drug Resistance in Bacterial Clinical Isolates by Two Simple Methods. Methods in Molecular Biology, 2010, 642, 143-157.	0.9	25

#	Article	IF	Citations
91	Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB. In Vivo, 2010, 24, 409-24.	1.3	35
92	Non-antibiotics reverse resistance of bacteria to antibiotics. In Vivo, 2010, 24, 751-4.	1.3	43
93	Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells. Anticancer Research, 2010, 30, 4867-71.	1.1	26
94	pH Modulation of Efflux Pump Activity of Multi-Drug Resistant Escherichia coli: Protection During Its Passage and Eventual Colonization of the Colon. PLoS ONE, 2009, 4, e6656.	2.5	53
95	The Vitamin B1 Metabolism of Staphylococcus aureus Is Controlled at Enzymatic and Transcriptional Levels. PLoS ONE, 2009, 4, e7656.	2.5	24
96	Geraniol Restores Antibiotic Activities against Multidrug-Resistant Isolates from Gram-Negative Species. Antimicrobial Agents and Chemotherapy, 2009, 53, 2209-2211.	3.2	207
97	Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 826-833.	2.3	246
98	SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). International Journal of Antimicrobial Agents, 2009, 33, 479-482.	2.5	32
99	In vitro activity of thioridazine against mycobacteria. International Journal of Antimicrobial Agents, 2009, 34, 190-191.	2.5	26
100	An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators. International Journal of Antimicrobial Agents, 2009, 34, 602-604.	2.5	27
101	The role of efflux pumps in macrolide resistance in Mycobacterium avium complex. International Journal of Antimicrobial Agents, 2009, 34, 529-533.	2.5	56
102	Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli. Journal of Biological Engineering, 2009, 3, 18.	4.7	164
103	Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression. Current Cancer Therapy Reviews, 2009, 5, 158-169.	0.3	6
104	Characterization of intrinsic efflux activity of Enterococcus faecalis ATCC29212 by a semi-automated ethidium bromide method. In Vivo, 2009, 23, 81-7.	1.3	8
105	Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method. Anticancer Research, 2009, 29, 2173-7.	1.1	10
106	Modelling of tumour--host coexistence In vitro in the presence of serine protease inhibitors. In Vivo, 2009, 23, 711-5.	1.3	0
107	Evaluation of cucurbitane-type triterpenoids from Momordica balsamina on P-glycoprotein (ABCB1) by flow cytometry and real-time fluorometry. Anticancer Research, 2009, 29, 3989-93.	1.1	5
108	Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. Journal of Antimicrobial Chemotherapy, 2008, 62, 504-513.	3.0	135

#	Article	IF	Citations
109	Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. International Journal of Antimicrobial Agents, 2008, 31, 198-208.	2.5	124
110	Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. International Journal of Antimicrobial Agents, 2008, 31, 458-462.	2.5	132
111	The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics. Future Microbiology, 2008, 3, 135-144.	2.0	9
112	Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. Journal of Antimicrobial Chemotherapy, 2008, 61, 1076-1082.	3.0	118
113	New Methods for the Identification of Efflux Mediated MDR Bacteria, Genetic Assessment of Regulators and Efflux Pump Constituents, Characterization of Efflux Systems and Screening for Inhibitors of Efflux Pumps. Current Drug Targets, 2008, 9, 760-778.	2.1	41
114	Promising Therapy of XDR-TB/MDR-TB with Thioridazine an Inhibitor of Bacterial Efflux Pumps. Current Drug Targets, 2008, 9, 816-819.	2.1	43
115	Editorial [Hot topic: Control and Regulation of Permeability of MDR Bacterial Pathogens to Antibiotics Presented by COST Action BM0701 (Guest Editors: L. Amaral and J.M. Pages)]. Current Drug Targets, 2008, 9, 718-718.	2.1	3
116	Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo, 2008, 22, 69-75.	1.3	23
117	Phenothiazines as Anti-Multi-Drug Resistant Tubercular Agents. Infectious Disorders - Drug Targets, 2007, 7, 257-265.	0.8	21
118	Antibiotic Stress, Genetic Response and Altered Permeability of E. coli. PLoS ONE, 2007, 2, e365.	2.5	184
119	Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. Journal of Antimicrobial Chemotherapy, 2007, 59, 1237-1246.	3.0	112
120	Prolonged exposure of methicillin-resistant Staphylococcus aureus (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype. International Journal of Antimicrobial Agents, 2007, 29, 302-305.	2.5	23
121	In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. International Journal of Antimicrobial Agents, 2007, 29, 338-340.	2.5	59
122	Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. International Journal of Antimicrobial Agents, 2007, 30, 242-249.	2.5	89
123	Antibacterial activity of ergosterol peroxide againstMycobacterium tuberculosis: dependence upon system and medium employed. Phytotherapy Research, 2007, 21, 601-604.	5.8	44
124	Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. In Vivo, 2007, 21, 237-44.	1.3	33
125	Elimination of plasmids by SILA compounds that inhibit efflux pumps of bacteria and cancer cells. In Vivo, 2007, 21, 635-9.	1.3	5
126	The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo, 2007, 21, 771-5.	1.3	30

#	Article	IF	Citations
127	"Non-Antibiotics": Alternative Therapy for the Management of MDRTB and MRSA in Economically Disadvantaged Countries. Current Drug Targets, 2006, 7, 887-891.	2.1	52
128	The Mechanism of Plasmid Curing in Bacteria. Current Drug Targets, 2006, 7, 823-841.	2.1	72
129	Reserpine, Ouabain and the Calcium Channel Blocker Verapamil, Cause Intracellular Killing of Staphylococcus aureus. Research Journal of Microbiology, 2006, 1, 203-209.	0.2	3
130	Thioridazine reduces resistance of methicillin-resistant staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In Vivo, 2006, 20, 361-6.	1.3	32
131	Synergistic interaction between proton pump inhibitors and resistance modifiers: promoting effects of antibiotics and plasmid curing. In Vivo, 2006, 20, 367-72.	1.3	18
132	An instrument-free method for the demonstration of efflux pump activity of bacteria. In Vivo, 2006, 20, 657-64.	1.3	29
133	Gamma delta T cell responses associated with the development of tuberculosis in health care workers. FEMS Immunology and Medical Microbiology, 2005, 43, 339-350.	2.7	16
134	Review: The phenothiazinium chromophore and the evolution of antimalarial drugs. Tropical Medicine and International Health, 2005, 10, 501-511.	2.3	90
135	Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus. FÃ¬toterapÃ¬Ã¢, 2005, 76, 96-99.	2.2	32
136	Direct Application of the INNO-LiPA Rif.TB Line-Probe Assay for Rapid Identification of Mycobacterium tuberculosis Complex Strains and Detection of Rifampin Resistance in 360 Smear-Positive Respiratory Specimens from an Area of High Incidence of Multidrug-Resistant Tuberculosis. Journal of Clinical Microbiology, 2005, 43, 4880-4884.	3.9	63
137	Inducement and Reversal of Tetracycline Resistance in Escherichia coli K-12 and Expression of Proton Gradient-Dependent Multidrug Efflux Pump Genes. Antimicrobial Agents and Chemotherapy, 2005, 49, 3578-3582.	3.2	110
138	The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient. In Vivo, 2005, 19, 733-6.	1.3	18
139	Increased Interleukinâ€4 Production by CD8 and Î³Î´ T Cells in Healthâ€Care Workers Is Associated with the Subsequent Development of Active Tuberculosis. Journal of Infectious Diseases, 2004, 190, 756-766.	4.0	95
140	Antimicrobial activity of phenothiazines. In Vivo, 2004, 18, 725-31.	1.3	60
141	Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo, 2004, 18, 787-94.	1.3	19
142	Carpobrotus edulis methanol extract inhibits the MDR ef?ux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation. Phytotherapy Research, 2003, 17, 512-519.	5.8	33
143	Phenothiazines alter resistance of methicillin-resistant strains of Staphylococcus aureus (MRSA) to oxacillin in vitro. International Journal of Antimicrobial Agents, 2003, 22, 250-253.	2.5	50
144	Since phenothiazines alter antibiotic susceptibility of microorganisms by inhibiting efflux pumps, are these agents useful for evaluating similar pumps in phenothiazine-sensitive parasites?. International Journal of Antimicrobial Agents, 2003, 22, 347-351.	2.5	14

#	Article	IF	Citations
145	Antiplasmid effect of promethazine in mixed bacterial cultures. International Journal of Antimicrobial Agents, 2003, 22, 217-222.	2.5	21
146	Enhancement of plasmid curing by 9-aminoacridine and two phenothiazines in the presence of proton pump inhibitor 1-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone. International Journal of Antimicrobial Agents, 2003, 22, 223-227.	2.5	25
147	Mycobacterial efflux pumps and chemotherapeutic implications. International Journal of Antimicrobial Agents, 2003, 22, 274-278.	2.5	67
148	Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2003, 47, 917-922.	3.2	191
149	Isoniazid-Induced Transient High-Level Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2002, 46, 2804-2810.	3.2	92
150	Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. International Journal of Antimicrobial Agents, 2002, 20, 34-43.	2.5	58
151	Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. Journal of Infection and Chemotherapy, 2002, 8, 227-231.	1.7	31
152	Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. International Journal of Antimicrobial Agents, 2001, 17, 225-228.	2.5	122
153	Phenothiazines: potential management of Creutzfeldtâ€“Jacob disease and its variants. International Journal of Antimicrobial Agents, 2001, 18, 411-417.	2.5	57
154	Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Tropical Medicine and International Health, 2001, 6, 1016-1022.	2.3	46
155	Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. Journal of Antimicrobial Chemotherapy, 2001, 47, 505-511.	3.0	116
156	Interaction between antibiotics and non-conventional antibiotics on bacteria. International Journal of Antimicrobial Agents, 2000, 14, 239-242.	2.5	39
157	The effects of chlorpromazine on the outer cell wall of Salmonella typhimurium in ensuring resistance to the drug. International Journal of Antimicrobial Agents, 2000, 14, 225-229.	2.5	22
158	Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. International Journal of Antimicrobial Agents, 2000, 16, 69-71.	2.5	69
159	Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies. International Journal of Antimicrobial Agents, 2000, 14, 173-176.	2.5	64
160	The potential management of resistant infections with non-antibiotics. Journal of Antimicrobial Chemotherapy, 1997, 40, 319-327.	3.0	138
161	Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. Journal of Antimicrobial Chemotherapy, 1996, 38, 1049-1053.	3.0	124
162	Ultrastructure alterations of Staphylococcus aureus exposed to RP59500. Journal of Antimicrobial Chemotherapy, 1994, 33, 625-628.	3.0	8

#	Article	IF	Citations
163	Synergic effect of chiorpromazine on the activity of some antibiotics. Journal of Antimicrobial Chemotherapy, 1992, 30, 556-558.	3.0	45
164	Predictive Value of Blood Cultures. Infection Control and Hospital Epidemiology, 1992, 13, 293-294.	1.8	1
165	Effects of chlorpromazine on the cell envelope proteins of Escherichia coli. Antimicrobial Agents and Chemotherapy, 1991, 35, 1923-1924.	3.2	36
166	Effects of low concentration of antibiotics. Antimicrobic Newsletter, 1990, 7, 65-70.	0.9	2
167	The post-antibiotic effect defined by bacterial morphology. Journal of Antimicrobial Chemotherapy, 1989, 23, 485-491.	3.0	53
168	Penicillin-binding site on the Escherichia coli cell envelope. Journal of Bacteriology, 1986, 167, 492-495.	2.2	14
169	Ratio of bacterial mass to colony-forming units: A new criterion for the study of susceptibility to antimicrobics. Infectious Diseases Newsletter (New York, N Y), 1985, 4, 75-77.	0.4	0
170	Sublethal Concentrations of Antibiotics, Effects on Bacteria and the Immune System. CRC Critical Reviews in Microbiology, 1982, 9, 101-138.	4.8	40
171	The Effect of Steroids on the Synthesis of RNA by Isolated T and B Lymphocytes of Normal Donors and Patients with Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 1981, 75, 382-387.	0.7	2
172	Cortisol resistant RPMI-1788 lymphocytes become sensitive to cortisol subsequent to a 24-h incubation period in medium containing purified human transcortin. Experientia, 1981, 37, 903-904.	1.2	7
173	Effects of beta-lactam antibotics on thymidine incorporation of bacteria. Current Microbiology, 1981, 5, 375-378.	2.2	3
174	Development, replication, and reversion of mecillinam-induced ovoid form ofSalmonella typhimurium. Current Microbiology, 1981, 5, 207-211.	2.2	1
175	Absence of alterations in antigenic determinats inSalmonella typhimurium after mecillinam-induced morphological changes. Current Microbiology, 1980, 4, 309-312.	2.2	1
176	Lymphopenic response of patients presenting with chronic lymphocytic leukemia associated with carcinoma of the prostate to diethylstilbestrol: Correlation of response to the in vitro synthesis of rna by patient lymphocytes and its relationship to transcortin. American Journal of Hematology, 1980, 8, 369-375.	4.1	26
177	Effect of Subminimal Inhibitory Concentrations of Mecillinam on the Synthesis of DNA, RNA, and Protein of Salmonella typhimurium: A Proposed Mechanism of Action*. Clinical Infectious Diseases, 1979, 1, 813-820.	5.8	7
178	Electrophoretic Abnormalities in Chronic Lymphocytic Leukemia and Cancer Sera. American Journal of Clinical Pathology, 1976, 65, 40-44.	0.7	0
179	Identification of breast cancer transcortin and its inhibitory role in cell-mediated immunity. Nature, 1976, 262, 589-590.	27.8	35
180	Placenta, transcortin, and localized immune response.. Journal of Clinical Investigation, 1976, 57, 1000-1008.	8.2	23

#	Article	IF	Citations
181	Effect of cortisol on the ultrastructure of normal, leukemic, and cultured human lymphocytes. In Vitro, 1975, 11, 212-223.	1.2	2
182	Serum B-12 binding as determined by the method of disc-acrylamide electrophoresis. Clinica Chimica Acta, 1975, 62, 341-348.	1.1	2
183	Pulmonary Lesions Induced by Chronic Exposure to Ozone. Archives of Environmental Health, 1974, 29, 164-166.	0.4	15
184	Quantitation of lactate dehydrogenase isoenzyme patterns of the developing human fetus. Clinica Chimica Acta, 1973, 45, 5-8.	1.1	16
185	Identification and Partial Purification of â€œTranscortinâ€•like Protein within Human Lymphocytes. Journal of Biological Chemistry, 1973, 248, 6398-6407.	3.4	66
186	Protein synthesis in human leukocytes and lymphocytes: 4. The effect of cortisol on RNA and protein synthesis in lymphocytes. Life Sciences, 1971, 10, 1039-1046.	4.3	14
187	The Response of Leukemic Lymphocytes to Cortisol: A Suggested Role of Transcortin. Blood, 1971, 37, 463-472.	1.4	17
188	Acrylamide Gel Electrophoretic Abnormalities in Chronic Lymphatic Leukemic Sera. American Journal of Clinical Pathology, 1971, 55, 65-67.	0.7	3
189	Transport of cortisol by cultured chronic lymphocytic leukemic lymphocytes. Experientia, 1971, 27, 511-512.	1.2	4
190	THE EFFECT OF CORTISOL ON THE INCORPORATION OF RNA AND PROTEIN PRECURSORS INTO THE NUCLEUS AND CYTOPLASM OF HUMAN NEUTROPHILS CULTURED IN VITRO. European Journal of Endocrinology, 1970, 65, 497-501.	3.7	2
191	Protein Synthesis in Human Leukocytes and Lymphocytes: 1. Effect of Steroids and Sterols. Blood, 1969, 34, 348-356.	1.4	28
192	An autoradiographic study of root cell differentiation in. Life Sciences, 1969, 8, 683-687.	4.3	1
193	THE EFFECT OF CORTISONE ON THE VOLUME AND TOTAL PROTEIN CONTENT OF MOUSE LIVER NUCLEI. Journal of Cell Biology, 1969, 42, 835-837.	5.2	2